Nyrada Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Nyrada has a total shareholder equity of A$5.1M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$5.9M and A$855.6K respectively.

Anahtar bilgiler

Borç/özkaynak oranı

AU$0

Borç

Faiz karşılama oranı	n/a
Nakit	AU$4.77m
Eşitlik	AU$5.05m
Toplam yükümlülükler	AU$855.63k
Toplam varlıklar	AU$5.91m

Son finansal sağlık güncellemeleri

Companies Like Nyrada (ASX:NYR) Can Afford To Invest In Growth

Jan 10

We're Keeping An Eye On Nyrada's (ASX:NYR) Cash Burn Rate

Feb 23

Recent updates

Shareholders Will Probably Not Have Any Issues With Nyrada Inc.'s (ASX:NYR) CEO Compensation

Nov 12

Companies Like Nyrada (ASX:NYR) Can Afford To Invest In Growth

Jan 10

We're Keeping An Eye On Nyrada's (ASX:NYR) Cash Burn Rate

Feb 23

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: NYR's short term assets (A$5.9M) exceed its short term liabilities (A$835.6K).

Uzun Vadeli Yükümlülükler: NYR's short term assets (A$5.9M) exceed its long term liabilities (A$20.0K).

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: NYR is debt free.

Borcun Azaltılması: NYR currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: NYR has sufficient cash runway for more than 3 years based on its current free cash flow.

Tahmini Nakit Akışı: NYR has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 10.1% each year

Nyrada Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Companies Like Nyrada (ASX:NYR) Can Afford To Invest In Growth

We're Keeping An Eye On Nyrada's (ASX:NYR) Cash Burn Rate

Recent updates

Nyrada Inc. has completed a Follow-on Equity Offering in the amount of AUD 3.359999 million.

Nyrada Inc., Annual General Meeting, Nov 12, 2024

Full year 2024 earnings released: AU$0.008 loss per share (vs AU$0.05 loss in FY 2023)

New major risk - Share price stability

New major risk - Market cap size

Nyrada Inc. has filed a Follow-on Equity Offering in the amount of AUD 1.965 million.

First half 2024 earnings released: EPS: AU$0.001 (vs AU$0.017 loss in 1H 2023)

Shareholders Will Probably Not Have Any Issues With Nyrada Inc.'s (ASX:NYR) CEO Compensation

Full year 2023 earnings released: AU$0.05 loss per share (vs AU$0.025 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Share price stability

First half 2023 earnings released: AU$0.017 loss per share (vs AU$0.018 loss in 1H 2022)

Nyrada Inc., Annual General Meeting, Nov 20, 2023

Nyrada Inc. Provides Update on the Progress of Its Brain Injury Program

Less than half of directors are independent

Nyrada Inc., Annual General Meeting, Nov 21, 2022

Nyrada Inc. Announces Efficacy Study Published in Journal of Lipid Research

Full year 2022 earnings released: AU$0.03 loss per share (vs AU$0.03 loss in FY 2021)

Nyrada Inc. Announces Board Changes

Nyrada Inc. Provides Cholesterol-Lowering Program Update

Nyrada Inc. Unveils Target of Its Brain Injury Program as TRPC Ion Channels & Provides Phase I Study Update

European Patent to be Granted for Cholesterol-Lowering Drug of Nyrada Inc

Less than half of directors are independent

Nyrada Inc. Announces Its Newest Brain Injury Drug Candidate

Nyrada Inc. Announces Its Newest Brain Injury Drug Candidate

Companies Like Nyrada (ASX:NYR) Can Afford To Invest In Growth

Nyrada Inc Provides an Update on the Progress of its Brain Injury Program

Nyrada Inc Announces Encouraging Efficacy Results from Its in Vivo Study of NYX-PCSK9i Called called APOE*3-Leiden.CETP

Nyrada Inc Announces New Potent Cholesterol-Lowering Candidates

Nyrada Inc. announced that it expects to receive AUD 11 million in funding

We're Keeping An Eye On Nyrada's (ASX:NYR) Cash Burn Rate

Nyrada Inc. Releases Update on the Company's Two Drug Development Programs

Nyrada Inc. Secures Collaboration with Walter Reed Army Institute of Research and UNSW

Nyrada Reports Further Results from Cholesterol Study

New 90-day high: AU$0.45

New 90-day high: AU$0.28

New 90-day high: AU$0.23

Full year earnings released - AU$0.095 loss per share

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin